We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Oral Bacteria May Cause Colorectal Cancer

By LabMedica International staff writers
Posted on 27 Aug 2013
Gut microbes have been linked to colorectal cancer, but it still unclear whether and how they might cause tumors to form in the first place. More...


Bacteria found in the mouth, known as Fusobacterium, stimulate poor immune responses, and turn on cancer growth genes to generate colorectal tumors; data, which could lead to more effective strategies for the early diagnosis, prevention, and treatment of colorectal cancer.

In recent studies, teams of scientists at the Dana-Farber Cancer Institute (Boston, MA, USA) found that Fusobacterium are prevalent in human adenomas, which are benign tumors that can become malignant over time, suggesting that these bacteria contribute to early stages of tumor formation. These bacteria accelerated the formation of tumors by attracting immune cells called myeloid cells, which invade tumors and stimulate inflammatory responses that can cause cancer.

In a separate study, scientists at the Case Western Reserve University (Cleveland, OH, USA) discovered that Fusobacterium nucleatum rely on a molecule called Fusobacterium adhesin A (FadA), which is found on the surface of these bacterial cells, to attach to and invade human colorectal cancer cells. FadA then turns on cancer growth genes, stimulates inflammatory responses in these cells, and promotes tumor formation. The FadA levels were much higher in tissues from patients with adenomas and colorectal cancer compared with healthy individuals. They also identified a compound that can prevent FadA's effects on cancer cells.

Wendy S. Garrett, MD, PhD, one of the senior authors, said, “Fusobacterium may provide not only a new way to group or describe colon cancers but also, more importantly, a new perspective on how to target pathways to halt tumor growth and spread." The authors concluded that unlike other bacteria linked to colorectal carcinoma, F. nucleatum does not exacerbate colitis, enteritis, or inflammation-associated intestinal carcinogenesis. However, their data suggest that, through recruitment of tumor-infiltrating immune cells, Fusobacterium generate a proinflammatory microenvironment that is conducive for colorectal neoplasia progression. The studies were published on August 14, 2013, in the journal Cell Host & Microbe.

Related Links:

Dana-Farber Cancer Institute
Case Western Reserve University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Electrolyte Analyzer
BKE-B
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.